- gsearch

Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov

Advanced Search

- gsearch

Search Results

Narrow Results:

2020 1

Antiviral Agents 1
Female 1
Humans 1
Immunization 1
Infant 1
Palivizumab 1
Pregnancy 1
Respiratory Syncytial Virus, Human 1
Respiratory Syncytial Virus Infections 1
Respiratory Syncytial Virus Vaccines 1

Journal Article 1

1 Results

Refine Results

All Collections

Refine Results:

All Collections

Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

CITE Title : Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants Personal Author(s) : Rainisch, Gabriel;Adhikari, Bishwa;Meltzer, Martin I.;Langley, Gayle; Published Date : 1 10 2020;1-10-; Source : Vaccine. 38(2):251-257 URL : https://stacks.cdc.gov/view/cdc/85252 Rainisch, Gabriel et al. (2020). Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. 38(2). Rainisch, Gabriel et al. "Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants" 38, no. 2 (2020) Rainisch, Gabriel et al. "Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants" vol. 38, no. 2, 2020 Export RIS Citation Information.

:

Rainisch, Gabriel ;

Adhikari, Bishwa

1 10 2020 | Vaccine. 38(2):251-257

:

Background:Palivizumab, a monoclonal antibody and the only licensed immunization product for preventing respiratory syncytial virus (RSV) infection, i...

To see more results, try removing search filters or changing the search terms